Analysts foresee more revenue Biogen

Tomorrow Biogen will publish it's past quarter's results. Over the current book year the total revenue will be 12,99 billion USD (consensus estimates). This is slightly more than 2017's revenue of 12,27 billion USD.

Historical revenues and results Biogen plus estimates 2018

The analysts expect for 2018 a net profit of 5,04 billion USD. For this year the consensus of Biogen 's result per share is a profit of 23,98 USD. The price/earnings-ratio is then 14,96.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Most recent target prices around 377 USD

The latest 3 recommendations for the biotech company were provided by Morgan Stanley , Piper Jaffray and Oppenheimer & Co.

Biogen 's market capitalization is based on the number of outstanding shares around 77,45 billion USD.

On Friday the stock closed at 358,71 USD.

Historical stock prices Biogen

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.